RNLXY
Renalytix plc
Key Financials
Operating Income
$-29608000
↑ 29.9%
Revenue
$2.3M
↓ 32.7%
Gross Profit
$156000
↓ 78.3%
Net Income
$-33456000
↑ 26.6%
EPS (Diluted)
$-0.31
↑ 43.6%
Total Assets
$8.0M
↓ 74.0%
Shareholders' Equity
$-7854000.00
↓ 212.7%
Cash & Equivalents
$4.7M
↓ 81.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 2/23/2026 | View on SEC |
| F-6 POS | 12/3/2025 | View on SEC |
| F-6 POS | 9/4/2025 | View on SEC |
| EFFECT | 7/30/2025 | View on SEC |
| EFFECT | 7/30/2025 | View on SEC |
| EFFECT | 7/30/2025 | View on SEC |
| EFFECT | 7/30/2025 | View on SEC |
| EFFECT | 7/30/2025 | View on SEC |
| 424B3 | 7/30/2025 | View on SEC |
| 15-12G | 7/30/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNLXY |
| Company Name | Renalytix plc |
| CIK | 1811115 |
| Sector | Services-Medical Laboratories |
| Industry | Emerging growth company |
| Exchange | OTC |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | X0 |
| Phone | 44 29 2071 0570 |